<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04208646</url>
  </required_header>
  <id_info>
    <org_study_id>CBM-ALAM.1-01</org_study_id>
    <nct_id>NCT04208646</nct_id>
  </id_info>
  <brief_title>Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Controlled Phase II Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells (AlloJoin®) for the Treatment of Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellular Biomedicine Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai 6th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cellular Biomedicine Group Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor
      Cells Therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Randomized, Double-blind, Controlled Phase II Trial of Allogenic Adipose
      Tissue-Derived Mesenchymal Progenitor Cells (AlloJoin®) Therapy for Knee Osteoarthritis.

      This is a multicenter, randomized, double-blinded, phase II clinical trial. Subjects who are
      with a clinical diagnosis of knee osteoarthritis cartilage defects and will be randomly
      distributed 1:1:1 to different group after signing the ICF and screening tests. Each group
      was treated for two cycles. The patients were followed up to 48 weeks after the first
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC Score</measure>
    <time_frame>24 weeks</time_frame>
    <description>The Western Ontario and McMaster Universities Osteoarthritis Index;0-96 points；96 points mean a worse outcome,will be tested at 24 weeks after the first injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI quantitative analysis of articular cartilage</measure>
    <time_frame>24 weeks,48 weeks</time_frame>
    <description>Magnetic Resonance Imaging analysis of articular cartilage, will be tested at 24、48 weeks after the first injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Score</measure>
    <time_frame>4、8、12、36、48 weeks</time_frame>
    <description>The Western Ontario and McMaster Universities Osteoarthritis Index;0-96 points；96 points mean a worse outcome, will be tested at 4、8、12、36、48 weeks after the first injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Score</measure>
    <time_frame>4、8、12、24、36、48 weeks</time_frame>
    <description>Visual Analogue Scale/Score；0-10 points；10 points mean a worse outcome,will be tested at 4、8、12、24、36、48 weeks after the first injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>4、8、12、24、36、48 weeks</time_frame>
    <description>The Medical Outcomes Study 36-Item Short-Form Health Survey;0-100 points；100 points mean a better outcome, will be tested at 4、8、12、24、36、48 weeks after the first injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>0d、1、3、4、8、12、24、25、27、28、36、48 weeks</time_frame>
    <description>AE and SAE, will be assessed at 0d、1、3、4、8、12、24、25、27、28、36、48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of laboratory test indexes and vital signs</measure>
    <time_frame>0d、1、3、4、8、12、24、25、27、28、36、48 weeks</time_frame>
    <description>Vital signs, physical examination, clinical laboratory tests:infectious disease check, blood coagulation test , blood check, urine check, blood biochemical test, immunological examination, tumor screening ,will be tested at 0d、1、3、4、8、12、24、25、27、28、36、48 weeks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Metabolic index detection</measure>
    <time_frame>0、4、8、12、24、36、48 weeks</time_frame>
    <description>Levels of cartilage metabolism and inflammatory biomarkers in serum and urine will be tested at 0、4、8、12、24、36、48 weeks</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Mesenchymal progenitor cells Dosage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesenchymal progenitor cells low-dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesenchymal progenitor cells Dosage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesenchymal progenitor cells high-dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No mesenchymal progenitor cells</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No mesenchymal progenitor cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal progenitor cells</intervention_name>
    <description>Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra- articular use</description>
    <arm_group_label>Mesenchymal progenitor cells Dosage 1</arm_group_label>
    <arm_group_label>Mesenchymal progenitor cells Dosage 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>No mesenchymal progenitor cells</intervention_name>
    <description>No mesenchymal progenitor cells for intra- articular use</description>
    <arm_group_label>No mesenchymal progenitor cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who understand and voluntarily sign the consent form before this study；

          2. According to the diagnostic criteria (American Rheumatology Association, clinical +
             radiology criteria), patients with knee osteoarthritis are definitely diagnosed；

          3. Age: 40-75, males and females；

          4. The diagnosis course of knee osteoarthritis was more than 6 months and less than 10
             years;

          5. The subjects' WOMAC score was 24-72, and the WOMAC pain score was 7-17 (the WOMAC
             score at least 48 hours after discontinuation of all painkillers);

          6. The Kellgren Lawrence grade (X-ray axial position of knee joint) of subjects was grade
             II / III;

          7. Subjects are generally in good condition and can walk autonomously, except for those
             who use wheelchairs, walking aids or crutches.

        Exclusion Criteria:

          1. The subject may be allergic to the main cell preparation components (B vitamins, amino
             acids and so on).

          2. The subject received systemic and / or local treatment with autologous and / or
             allogeneic mesenchymal progenitor cells.

          3. The subject has a BMI of over 30.

          4. Laboratory test (any item meets): neutrophil absolute number &lt; 1.0 × 10^9 / L,
             platelet count &lt; 50 × 10^9 / L, serum albumin &lt; 30g / L, serum creatinine &gt; upper
             limit of normal value range, total bilirubin、alanine aminotransferase、aspartate
             aminotransferase &gt; upper limit of 2 times of normal value range.

          5. The subject has diseases or symptoms may affect VAS, WOMAC and so on.

          6. The subject has serious and poorly controlled concomitant diseases, such as (but not
             limited to) nervous system, cardiovascular, liver, kidney, gastrointestinal and
             endocrine diseases, which may prevent the subjects from participating in the study
             according to the judgment of the researchers.

          7. The subject has an history malignant tumour.

          8. The subject has connective tissue disease or rheumatoid
             arthritis、chondropathy、Chondrocalcinosis articularis、 Hemochromatosis、inflammatory
             arthropathy、avascular necrosis of femoral head、Paget's disease、hemophilic
             arthropathy、infectional arthritis、Charcot' s disease、villonodular synovitis or
             synovial chondromatosis.

          9. The subject has severe generalized infectious diseases or local knee infection
             (including skin and intra-articular infection) in the 3 months prior to this trial.

         10. The subject has disease of lower limbs which may be interfered knee evaluation, for
             example fibromyalgia, osphyalgia, lumbar disc protrusion and so on.

         11. The subject had any other coagulation dysfunction caused by acute or chronic diseases,
             according to the judgment of the researchers, this coagulation dysfunction may
             endanger the safety of patients and / or affect the judgment of knee joint evaluation
             indicators.

         12. The subject has received arthroscopic surgery or other open surgery related to knee
             joint operation in the 6 months prior to this trial.

         13. The subject has received other intra-articular injections, including but not limited
             to hyaluronic acid, hormone, PRP, BMP (bone morphogenetic protein) , hypertonic
             glucose and so on for KOA in the 3 months preceding the trial.

         14. The subject has received aminoglucose or chondroitin sulfate within 1 month before the
             treatment.

         15. The subject has used dexamethasone, prednisone, hydrocortisone and other hormones
             orally / intravenously within 1 month before the treatment.

         16. The subject has undergone knee prosthesis or a plan of knee prosthesis within the
             trial.

         17. The subject has contraindication of MRI, included but not only: the subject installed
             heart pacemaker, defibrillator, heart bracket, heart valve prosthesis, metal clip
             after aneurysm surgery, drug infusion device implanted in vivo, any electronic device
             implanted in the body (nerve stimulator, bone growth stimulator) endovascular coil,
             strainer, ECG monitor, metal suture, shrapnel or sand of body, plate fixation and
             steel nail after fracture surgery, artificial cochlea, middle ear shift plant,
             metallic intraocular foreign body etc; the subject is a claustrophobia, critical ill
             patient and so on.

         18. The subject tests positive for: HIV, HBV, HCV and treponema pallidum.

         19. The subject has history of alcoholism, drug abuse, or mental illness in the 3 years
             prior to this trial.

         20. The subject has participated in any other clinical trial in the 3 months prior to this
             trial.

         21. The subject (including male subjects) has fertility, sperm donation or egg donation
             plans in the next 3 months; the female subject is pregnant, lactating or having a
             positive pregnancy test.

         22. The subject is legally disabled by reference to the law of the people's Republic of
             China on the protection of disabled persons (April 2008).

         23. The subject has any other unsuitable condition (such as factors reducing the follow-up
             compliance) to be determined by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunde Bao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiaotong University School of Medicine, Renji Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Changqing Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai 6th People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guochun Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>China-Japan Friendship Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chengqing Yi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shigui Yan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Weiguo Wan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunde Bao, M.D. &amp; Ph.D.</last_name>
    <phone>021-587523545</phone>
    <email>xck@renji.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Guochun Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Shigui Yan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weiguo Wan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Chengqing Yi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiaotong University School of Medicine, Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Chunde Bao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Changqing Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

